Your session is about to expire
← Back to Search
mycophenolate mofetil for Lymphoma
Study Summary
This trial is testing two different doses of a drug to see which is better at preventing GVHD following a stem cell transplant. The trial will adapt based on T cell counts to see which dose is better at preventing relapse and GVHD.
- Lymphoma
- Hodgkin's Lymphoma
- Lymphocytic Leukemia
- Multiple Myeloma
- Acute Lymphoblastic Leukemia
- Non-Hodgkin's Lymphoma
- Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Myelodysplastic Syndrome
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2009 Phase 3 trial • 252 Patients • NCT02005562Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Can middle-aged adults join in this research project?
"This study is recruiting patients aged 18-74. Out of the 1002 trials for patients under 18 and 4616 trials for patients over 65, this is the only one that meets the age requirements."
Mycophenolate mofetil is most often given to treat which condition?
"Mycophenolate mofetil is not only used to treat the steroid therapy, but also severe idiopathic neutropenia, acute lymphoblastic leukemia (all), and hemopoietic stem cell transplant."
What is the most severe reaction that patients have had to mycophenolate mofetil?
"While there is some evidence of mycophenolate mofetil's safety, it is only from Phase 2 trials. None of the trials have yet found it to be an effective medication."
Are there any available vacancies for individuals in this experiment?
"This trial is not currently looking for new participants. According to the posting date and most recent update, the study was active between 2015 and 2020. There are currently 4946 trials actively admitting patients with leukemia, lymphocytic and 317 studies for mycophenolate mofetil actively admitting patients."
Share this study with friends
Copy Link
Messenger